Correction to: Ann Surg Oncol https://doi.org/10.1245/s10434-020-08407-8
In the original article, the survival curves are missing in Fig. 1c and d. Following is the corrected Fig. 1.
Kaplan–Meier curves for recurrence and survival by symptom status at recurrence. a Recurrence-free survival stratified by AJCC stage. b Survival of patients treated with any systemic therapy for metastatic recurrence stratified by symptom status at recurrence [median survival 21.2 (ASDR) vs. 7.6 months (SR); HR 2.16, 95% CI 1.30–3.59; p = 0.003]. c Survival of patients treated with anti-PD1 therapy for metastatic recurrence, stratified by symptom status at recurrence [median not reached (ASDR) vs. 13.6 months (SR); HR 1.99, 95% CI 0.69–5.72; p = 0.2]. d OS from the start of surveillance stratified by symptom status at recurrence [median survival time 39.2 months (ASDR) vs. 23.2 months (SR); HR 1.59, 95% CI 1.10–2.31; p = 0.02]. OS overall survival, HR hazard ratio, CI confidence interval, AJCC American Joint Committee on Cancer, ASDR asymptomatic surveillance-detected recurrence, SR symptomatic recurrence, PD1 programmed death receptor-1
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ibrahim, A.M., Le May, M., Bossé, D. et al. Correction to: Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence. Ann Surg Oncol 27 (Suppl 3), 976–977 (2020). https://doi.org/10.1245/s10434-020-08618-z
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-08618-z